Tofacitinib Associated with Reduced Intubation Rates in the Management of Severe COVID-19 Pneumonia: A Preliminary Experience

BACKGROUND: The second wave of COVID-19 pandemic was not only associated with a rapid and severe surge in the number of cases but also limited availability of recommended medicines. Baricitinib has been known to reduce recovery time in COVID-19 pneumonia in association with remdesivir. Tofacitinib,...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Pawan K, Lalwani, Lokesh K, Govindagoudar, Manjunath B, Aggarwal, Richa, Chaudhry, Dhruva, Kumar, Prashant, Gehlaut, Preeti
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Jaypee Brothers Medical Publishers 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645820/
https://www.ncbi.nlm.nih.gov/pubmed/34916741
http://dx.doi.org/10.5005/jp-journals-10071-23964

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8645820/
https://www.ncbi.nlm.nih.gov/pubmed/34916741
http://dx.doi.org/10.5005/jp-journals-10071-23964

Ejemplares similares